Pregabalin Extended Release

75,845 adverse event reports submitted to the FDA (2004–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Pregabalin Extended Release in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Pregabalin Extended Release adverse event reports by reporter sex
SexReports
Female39,928
Male27,842
Unknown93

By Age Group

View age group data as a table
Pregabalin Extended Release adverse event reports by reporter age group
Age groupReports
0-171,609
18-347,008
35-4911,767
50-6416,422
65-7410,956
75+10,251

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Pregabalin Extended Release. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Pregabalin Extended Release adverse event reports by reported outcome
OutcomeReports
Other Serious43,912
Hospitalization31,754
Death11,470
Non-Serious9,759
Life-Threatening6,524
Disability4,233

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Pregabalin Extended Release. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Pregabalin Extended Release adverse event reports by year
YearReports
20043
20054
200659
2007211
2008462
2009367
2010548
2011571
2012825
20131,052
20141,156
20151,629
20162,143
20172,594
20184,031
20195,756
20207,496
20218,297
20228,595
20238,261
20249,785
20259,838
2026 (partial)2,162

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Pregabalin Extended Release

In FDA adverse event reports that mention Pregabalin Extended Release, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026